Skip to content

Study · Case report or series · n = 1 · 2022

2 results

Progressive Cholestasis and Biliary Cirrhosis After Initiating Oral Semaglutide: Report From the Drug-Induced Liver Injury Network.

Ma J, Mathur K, Muldoon JL, Ghabril M, Chalasani N, Vuppalanchi R

ACG case reports journal26 Dec 2022Cited by 8 (Europe PMC)

PMID36600793 (opens in a new tab)PMCIDPMC9794239 (opens in a new tab)DOI10.14309/crj.0000000000000922 (opens in a new tab)PepBankPUB-36600793
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 51-year-old man with type 2 diabetes, jaundice presented 6 months after starting oral semaglutide, and the liver injury progressed to biliary cirrhosis with no alternative etiology found.

    In plain wordsIn one man with type 2 diabetes, liver injury and cirrhosis followed 6 months of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseCholestatic liver injury progressing to biliary cirrhosis
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated · oral · 6 months before presentationAs given in this study (human).

    Source sentences

    Summary
    The case involved a 51-year-old man with type 2 diabetes who presented with jaundice and acute-on-chronic kidney disease 6 months after starting oral semaglutide.
    2 context sentences
    Summary · context
    His liver injury progressed to biliary cirrhosis, accompanied by nephritis that led to end-stage renal disease.
    Summary · context
    Extensive evaluations including liver and kidney biopsies revealed no alternative etiologies.
  2. 02HumanCase report or seriesSafety outcome

    In a 51-year-old man with type 2 diabetes, nephritis that led to end-stage renal disease accompanied liver injury after oral semaglutide was started.

    In plain wordsIn one man with type 2 diabetes, kidney failure came with liver injury after he started oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    IncreaseNephritis leading to end-stage renal disease
    Study

    n = 1

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated · oral · 6 months before presentationAs given in this study (human).

    Source sentences

    Summary
    His liver injury progressed to biliary cirrhosis, accompanied by nephritis that led to end-stage renal disease.
    1 context sentence
    Summary · context
    The case involved a 51-year-old man with type 2 diabetes who presented with jaundice and acute-on-chronic kidney disease 6 months after starting oral semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.